Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility.

Conditions

Multiple Myeloma

Interventions

DRUG: Carfilzomib 20 mg/m^2
DRUG: Carfilzomib 70 mg/m^2
DRUG: Dexamethasone 40 mg
DRUG: Dara-SC 1800 mg
DRUG: Dexamethasone 20 mg

Sponsor

Janssen Research & Development, LLC